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ABSTRACT
Although, several categories of nosocomial infections are presented during the recent years, urinary tract 
infections (UTIs) considered as one of the most important systemic infections. The presence of Candida 
species in the urinary tract system (Candiduria) is seen in only 10-15% of the cases with UTI, however can-
diduria has been considered as more problematic infection for patients, laboratory workers and physicians. 
Due to increasing numbers of several predisposing factors, such as antibacterial agents, urinary tract instru-
mentation, diabetes mellitus, invasive therapies, and prolonged hospital stay, candiduria develops among the 
hospitalized patients, especially hospitalized in intensive care units (ICUs) and neonatal intensive care units 
(NICUs). According to the epidemiological studies, Candida albicans is the most common isolated species 
from candiduric patients. However, during the recent years, due to increasing resistance to antifungal drugs, 
non-albicans Candida species including, C. glabrata, C. krusei, C. parapsilosis and C. tropicalis have been 
also implicated. We found that the mean prevalence of candiduria among Iranian patients was lower (16.5%) 
than worldwide ratio and also males were more frequently affected than females (M:F, 1.2:1). Similar to 
other countries, C. albicans was most common infectious agent followed by non-albicans Candida species 
including, C. glabrata, C. tropicalis and C. krusei. 
Keywords: Candiduria; Candida albicans; Candida species; Iran; urinary tract infection.
Introduction
Urinary tract infections (UTIs) are the most com-
mon nosocomial infections among the hospital-
ized patients and their incidence has considerably 
increased during the recent decades.[1-4] Several 
microorganisms are associated with UTIs includ-
ing, bacteria, viruses, filamentous and yeasts 
fungi, however 10-15% of them are caused by 
Candida species, common fungal mycoflora.[5] 
Funguria is a general term for the presence of sev-
eral species fungi in the urinary system, such as 
moulds (Aspergillus, Penicillium, Cladosporium, 
and Geotrichum species).[6-11] However, the pres-
ence of Candida species in urine are considered 
as candiduria and its severity varies from asymp-
tomatic candiduria to clinical sepsis.[12,13] In addi-
tion, candiduria was defined as the presence of 
Candida >104 CFU/mL (colony forming unit / 
mL of urine) together with pyuria (>10 polymor-
phonuclear leukocytes/mm3).[14] 
On the other hand, some urologists believe that 
there are no clear criteria or available recom-
mendations for candiduria. So, candiduria may 
indicate contamination of the urine samples, 
lower urinary tract colonization with Candida, or 
true invasive infection of the upper and/or lower 
urinary tract caused by Candida species.[15] As a 
result, there are several responses by physicians 
considering the finding of organisms in the urine. 
The incidence rate of candiduria varies in differ-
ent reports from different areas.[9,12,16,17]
Clinical and research consequences
Urinary tract infections due to fungi are occurring 
most commonly as a part of systemic mycosis 
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in patients with predisposing factors including immunodeficiency, 
long-term hospital stays in intensive care unit (ICU) and neonatal 
intensive care units (NICU), long-term antibiotherapy and che-
motherapy, indwelling catheters and elderly patients.[9,12,15,18-20] In 
addition, some researchers have believed that the incidence of can-
diduria in teaching hospitals increased due to use of broad-spectrum 
antibiotics.[18] The new invasive therapies are also raised the inci-
dence of candiduria among patients with cancer and neutropenia.
[4,21] In some studies, the mortality rate in candiduria was high and 
antifungal therapy could not make a significant difference in mortal-
ity rates (30%).[19,22] Furthermore, the virulence factors of Candida 
species have an important role in mortality rates.[20] During the last 
2-3 decades increasing incidence rates in non-C. albicans species of 
Candida such as, Candida glabrata, C. tropicalis, C. krusei and C. 
parapsilosis have been observed that caused a major problem among 
hospitalized patients due to high resistance to antifungal drugs.[23,24]
Considering the above-mentioned facts, the increasing knowl-
edge of clinicians, researchers and laboratory workers about 
candiduria, causative agents, laboratory identification methods, 
and antifungal susceptibility, have an important role in the 
prophylaxes and effective treatments as well as more accurate 
selection of antifungal agents for candiduric patients.
Search strategy and study selection
The searching terms were candiduria, UTI, funguria, and candi-
duric patients. All papers published in full text in English and/
or Persian have been selected for review and suitable data have 
been extracted. Published papers were searched via PubMed, 
Scopus and Google Scholar. The search of the Iranian literatures 
was performed by using the international resources; Medline 
database through PubMed (http://www.ncbi.nlm.nih.gov/
pubmed), Scopus (http://www.scopus.com), Google Scholar 
(http://scholar.google.com), Google (http://www.google.com) 
and ISC (http://www.isc.gov.ir/). Moreover, local databases 
such as, Magiran (http://www.magiran.com) and SID (http://
www.sid.ir) have been also searched. 
Predisposing factors related to host
Although, Candida species, especially C. albicans are part of 
human normal mycoflora, candiduria is rarely present in healthy 
individuals. On the contrary, it is mostly found in hospitalized 
patients (ICU and NICU patients) and patients with predispos-
ing factors.[9,25] The impairment of host defense mechanisms 
(cellular and humoral defenses), damage in anatomical human 
barriers (burns, invasive surgeries, skin maceration), and under-
lying diseases can cause an imbalance in the host defence mech-
anism.[21,23] As a result, the tissues of the hosts are invaded by 
normal commensal organisms. Patients in both ICU and NICU 
have often several predisposing factors, such as, diabetes mel-
litus, immunosuppressive therapy, prolonged antibiotherapy, 
advanced age, previous surgery (urological and non-urological), 
leukemia, chronic renal failure, renal transplantation, malignan-
cy, neutropenia, genitourinary tuberculosis and bone marrow 
transplantation.[9,15,19,20,26-29] Usually, up to 20% of hospitalized 
patients (especially ICU, NICU patients) may expose to candi-
duria throughout their hospitalization due to invasive therapeu-
tic and diagnostic procedures.[14,23] Corticosteroid therapy, and 
patients with hematologic malignancies may also contribute to 
the development of candiduria among patients.[14,30,31] 
Female sex, nephrolithiasis, urinary tract obstruction, the 
presence of stones and benign prostatic hyperplasia are other 
predisposing factors for candiduria.[1,27,32] In addition, urinary 
tract instrumentation such as insertions of Foley catheters, 
double-J stenting, suprapubic catheters, nephrostomy tubes and 
hemodialysis were also noted as the predisposing factors for 
candiduria.[15-17,33] The role of duration of catheterization and 
antibiotic therapy in the increasing incidence of candiduria has 
been well discussed in the literature.[1,15,34] Catheters are bioma-
terials that cause biofilm formation and serve as a portal of entry 
for Candida into the urinary system. Some reports show that 
78% of the patients carrying urinary devices have candiduria.
[15] On the other hand, the dramatic increase in the prevalence 
of candidiasis was also observed among patients with acquired 
immunodeficiency syndrome (AIDS).[35,36] Also, such patients 
have a high risk of morbidity and mortality.[36]
In Paul et al.[20] study, the class of cephalosporins was the most 
commonly prescribed antimicrobial agents for patients in whom 
candiduria was detected. Other researchers believed that there 
was a strong correlation between candiduria and uncontrolled 
intake of broad-spectrum antibiotics[24], for example, use of anti-
microbial agents as meropenem and ceftazidime.[18] Generally, 
Guler et al.[21] believed that incidence rates of candiduria 
increase due to urinary catheterization (12-fold), antibiotic use 
and urinary tract abnormalities (6-fold), abdominal surgeries 
(4-fold), diabetes mellitus (2-fold), corticosteroid and immune 
suppressive administration (1.4-fold). 
Pathogenicity of Candida
Candida species, especially C. albicans are harmless commen-
sal yeasts, and a lifelong resident of human body that cause 
several superficial, cutaneous, and systemic infections under 
suitable circumstances. Although the predisposing factors of 
host have an important role in the development of candidiasis, 
many pathogenicity factors are associated with microorganism 
for invading host tissues. Several factors are associated with the 
pathogenicity of Candida including; biofilm formation, extra-
cellular enzymes, germ tube formation and phenotype switching 
phenomena.[20,37-44] Several studies have shown that the secretion 
of hydrolytic enzymes, such as proteases, phospholipases, and 
lipases have an important role in the pathogenesis of Candida 
species.[43,45] Adherence to the tissue surfaces, heat shock 
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proteins, galvanotropism, and thigmotropism have also been 
demonstrated and may contribute to the subsequent UTI.[41,46] In 
addition, some of these factors such as biofilm formation can 
interfere with antifungal therapy.[5,44] On the other hand, rou-
tine antifungal prophylaxis may increase the pathogenicity of 
Candida and resistance to antifungal drugs.[47,48] 
Microbiology of candiduria
A broad variety of fungi are associated with fungal UTIs 
including, filamentous fungi (Aspergillus and Penicillium spe-
cies), Cryptococcus and Candida species.[2,6,7,9,16,49] Various 
ecosystems such as soils, foods and water are the main sources 
of Candida species. In addition, several species of Candida 
(especially, C. albicans) are the mycobiota of gastrointestinal 
tract, vaginal mucosa, urethra and lungs in humans and animals. 
They are also as transit saprophytes and colonizing skin and nail 
of human body. Several reports have shown that nearly 10-15% 
of nosocomial UTIs are usually caused by Candida species[5] 
and out of more than 200 species of the genus Candida, only 12 
species are associated with different types of candidiasis.[2,15,35,48] 
Candiduria is most commonly caused by C. albicans that are 
detected in 50-70% of urinary isolates, followed by C. glabrata 
(20% ) and C. tropicalis.[9,17,24,27,29,50] However, incidence rates of 
other non-albicans Candida species; such as C. parapsilosis, C. 
lusitaniae, C. guilliermondii and C. krusei have also increased 
during last decades.[16,22,37,51] In a study conducted by Paul et 
al.[20], in India C. tropicalis with an incidence rate of 30.5% 
was the most common microorganism isolated from candi-
duric patients followed by C. albicans. Although, coinfection 
with bacteria is more common among patients, polymicrobial 
infections with several yeast species were reported in 5-10% of 
Candida-related UTIs. Interestingly, in most cases, C. glabrata 
appears to be a frequent pathogen in combination with other 
species.[9,12,16] In addition Trichosporun and Geotrichum species 
are rarely isolated from urine samples.[8,9,52]
Epidemiology, sex and age distribution of candiduria
Naturally, due to anatomical and functional characteristics of 
the urinary tract system, the incidence of candiduria is higher 
among females than males.[1,21,27] In addition, some of the 
researchers have believed that this high incidence of candiduria 
among women may reflect vaginal candidiasis.[15,27] The inci-
dence of candiduria was reported as 57.8% among women by 
Artiaga Kobayashi et al.[27] in Brazil, 61.9% by Hassaneen et 
al.[24] in Egypt and 76% by Dalen et al.[34] in Ottawa, Canada. 
Reports have shown that candiduria develops in different age 
groups ranging from three months to 81 years.[4,53-55] Several 
studies have shown that there is a significant association 
between female gender and candiduria among the HIV-infected 
patients and ICU patients.[31,36] In addition, in a report from 
Egypt Hassaneen et al.[24] found that candiduria was more preva-
lent among female gender, with a female/male ratio of 1.62. On 
the other hand, Paul et al.[20] indicated that the male:female ratio 
among candiduric patients was 1.08. 
The study has shown that the the incidence of nosocomial UTIs 
due to Candida species increased 22-40% during 1992-1997 
when compared with the time interval between 1986, and 1989.
[2] Several reports from around the world show that the preva-
lence of candiduria varies between countries (Egypt 14%[24], and 
Brazil 22%[27]). In a study, 7.5% and 17.1% of diabetic patients 
had asymptomatic and symptomatic candiduria, respectively 
with overall prevalence of 8.3% in Ethiopia.[56] 
Direct microscopic examination and urine culture 
Suprapubic urine sample is the best urine sample to be used for 
the diagnosis of candiduria; however the second sterile urine 
samples are usually used. Asymptomatic catheter-associated 
candiduria is defined as the presence of a microorganism at 
a minimum concentration of 103 CFU/mL in a urine culture, 
in the absence of signs and symptoms of a UTI.[34] There are 
no sensitive/specific laboratory diagnostic tests to distinguish 
infection from colonization in urine samples. According to 
literature candiduria can be demonstrated in symptomatic or 
asymptomatic UTIs. 
The presence of Candida species in both direct microscopic 
examinations and/or cultures of urine samples couldn’t specifi-
cally confirm the presence of UTI. In all candiduric conditions, 
including contamination, colonization of catheter and infection, 
Candida species may be isolated from urine samples. Although, 
routinely the second urine samples were collected into the ster-
ile urine bottles (for adults) and disposable urine collection bags 
(for neonates and children), suprapubic specimens are the best 
urine samples to be used for diagnostic purposes.[15]
Routine mycology laboratory culture media, such as 
Sabouraud dextrose agar (SDA), potato dextrose agar (PDA), 
and nutrient agar with or without an antibacterial are usually 
used for culture. In addition, during the two last decades a 
relatively new culture medium (CHROMagar Candida) was 
incorporated in medical mycology laboratories.[9,24] One of 
the most important advantages of CHROMagar Candida is to 
detect polymicrobial growth in urine cultures (Figure 1).[9,54] 
Although, the best temperature for incubation under aerobic 
conditions is 35-37°C maintained for 24-48 hours, for slow 
growing species ambient temperature for one week has been 
reported.
Urine specimens were usually stained with Gram, Giemsa or 
methylene blue dyes. In addition, wet mount preparation from 
the urine sediment can be used for direct examination. Presence 
of ovoid shaped yeast cells, budding cells (3-15 µm) and pseu-
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dohyphae are identifying features of positive direct smears. 
Candidoma (fungus ball) or granular cyst containing yeast 
cells, budding cells and pseudohyphae of Candida are found 
in urine samples (Figure 2). The presence of renal fungal balls 
has been reported in 12% of the cases.[22] Fungal balls are the 
most frequent manifestation of renal candidiasis in hospitalized 
neonates in a NICU. Identification of species is usually applied 
in specific and research laboratories and general laboratories in 
hospitals can only identify yeast or C. albicans. Hence, clini-
cians always overlook non-albicans Candida species that are 
more resistant to antifungal therapy. 
The colony count of Candida species in urine samples is an 
important tool for clinicians in their decision-making process 
for either finding an effective antifungal for patients or remov-
ing urinary catheter. Furthermore, monitoring the treatment 
process is actually completed by checking the colony count 
during treatment. Although, candiduria has been defined as 
the presence of Candida species more than 104 CFU/mL in 
urine samples[14], Bukhary believed that clinically significant 
renal candidiasis might develop even with low colony counts 
(1000 CFU/mL).[15] Furthermore, the colony counts more than 
105 CFU/mL, are usually associated with long-term indwelling 
urethral catheters.[1]
In vitro antifungal assay
Although, antimicrobial-surveillance programmes are provid-
ing useful information for empirical therapy, species assign-
ment as well as in vitro antifungal assay are usually applied 
in the specific medical mycology laboratories. As a result, all 
clinicians have not a specific antifungal susceptibility profile 
against Candida isolates. On the other hand, widespread use of 
antifungal agents, and increased number of opportunistic fungal 
infections have increased resistance to available drugs. In the 
1990s, azole-resistant isolates of C. albicans were found among 
HIV patients who were receiving long-term antifungal therapy, 
particularly fluconazole.[57] Literatures have shown that resis-
tance against Candida species was first observed against fluco-
nazole and increased progressively during several last decades.
[58,59] Furthermore, resistance against other antifungals such as 
amphotericine B, caspofungin, posaconazole and itraconazole 
was also reported.[51,60-63]
Out of several antifungal identification tests, microdilution test 
is the most popular one among medical mycology researchers 
and CLSI and EUCAST defined specific breakpoints for some 
clinical important fungi.[25] Recently, modified microdilution 
technique using Resazurin (colorimetric method) was employed 
for antifungal susceptibility tests due to rapid measurement of 
minimum inhibitory concentration (MIC).[25,28,64] E-test and disk 
diffusion tests are simple and user friendly for laboratory tech-
nicians, however these tests were less frequently used by scien-
tists due to their rare availability and lower accuracy. Agar well 
diffusion is another antifungal assay that is usually used for the 
evaluation of the in vitro antifungal activity with plant extracts.
[65] Totally, MIC was measured as MIC ranges, MIC50, MIC90 
and MICGM according to above tests for antifungal evaluation 
in vitro. These parameters are relatively associated with clinical 
outcomes of patients.
Interventions and outcomes
The treatment of candiduria is related to several key factors 
including presence of a confirmed candiduria using a second, 
clean-voided urine culture, physical examination, a detailed his-
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Figure 1. Growth of multi species Candida on CHROMagar 
Candida medium
Figure 2. a, b. Yeast cells, budding cells and pseudohyphae of 
Candida albicans in urine sample (a: Fuchsin stained 100×; 
b: Wet smear)
a b
tory to look for signs or symptoms and the presence of predis-
posing factors. Although, amphotericin B was traditionally the 
unique systemic antifungal for UTIs, its toxicity prevented its 
widespread use for all clinical forms of candiduria and Candida 
species.[66,67] Furthermore, new antifungals such as, fluconazole, 
flucytosine, voriconazole, itraconazole, posaconazole, isavu-
conazole and echinocandins (caspofungin) are introduced for 
therapy during last decades.[50,66-70] 
Asymptomatic catheter-associated candiduria is usually a tran-
sient and benign condition, and does not associate with invasive 
candidiasis. In these cases, especially in adult patients hospital-
ized in ICUs, candiduria presents as fungal colonizations, and 
antifungal therapy is not required. Disease is resolved spon-
taneously when catheter is removed. Although asymptomatic 
candiduria does not need systemic antifungal therapy[18,34], phy-
sicians need to confirm the infection by a second sterile urine 
sample. On the other hand, some authors have believed that 103 
CFU/mL of Candida in urine is sufficient for the diagnosis of 
infection and immunocompromised patients (diabetes mellitus, 
leukemia, organ transplants) should be treated with systemic 
antifungals.[15]
Voltan et al.[23], have believed that UTI due to non-C. albicans 
species such as, C. glabrata, C. tropicalis, C. krusei, and C. 
parapsilosis constitute major problems in the hospital environ-
ment. Incidence of urinary tract infections due to C. glabrata 
has increased during last decades.[27] Studies have demonstrated 
that prescribing oral fluconazole for a short-term was effective 
for the eradication of Candida from urine.[27] However, treating 
candiduria due to non-albicans Candida species can be diffi-
cult because of resistance to fluconazole.[50] Saha et al.[51], have 
believed that innate resistance of C. krusei to fluconazole may 
result from hospital practice of empirical administration of the 
drug which lead to selection of resistant species.
On the other hand some studies have shown that mortal-
ity rate of 26.2% was seen among candiduric patients and the 
most common predisposing factors associated with death are 
related to urinary tract instrumentation devices, antimicrobial 
therapy, ICU hospitalization, renal failure, and use of umbilical 
venous catheter.[20,25] However, candiduria among the critically 
ill newborn in NICUs can be a sign of a disseminated infec-
tion, especially candidemia. Although, spontaneous resolution 
occurred among patients with asymptomatic candiduria in sev-
eral studies, treatment with fluconazole eradicated candiduria in 
60.8%[27]-50% of the cases.[71] 
Generally, fluconazole is the first choice antifungal drug for 
candiduria, however in resistant cases, flucytosine is a useful 
alternative.[72] During the last decades, new effective antifungals 
belonging to echinocandin class were introduced into clinical 
usage. In a case series study, Lagrotteria et al.[50] found that 
micafungin may be used for the treatment of candiduria due to 
less susceptible strains of non-albicans species. 
Candiduria in Iran
The Islamic Republic of Iran is located in western Asia, north 
of Persian Gulf and Oman Sea. It is the second-largest country 
in the Middle East with 1,648,195 km2 and with over 81 million 
inhabitants. The first available documented data about candi-
duria in Iran was reported by Zaini et al.[73], in 1993 and more 
recently published papers have illustrated candiduria pattern in 
Iranian hospitals so far. Disease is approximately widespread in 
Iranian people, however, its frequency vary in different prov-
inces. The mean prevalence of candiduria was approximately 
16.5% in Iran, with highest rate (32.3%) in Qazvin and the low-
est in Khuzestan (5.2%).[12,53] 
Totally in Iran the most common etiologic agents of candiduria 
were C. albicans (58.53%), followed by C. glabrata (15.39%), 
C. tropicalis (5%), C. krusei (2.72%), C. parapsilosis (1.53%), 
C. kefyr (1.03%), C. lusitaniae (0.42%) and Candida species 
(14.72%). Furthermore, uncommon yeast / yeast-like micro-
organisms such as C. albidus (0.23%), C. laurentii (0.07%), 
Geotrichum (0.12%) and unidentified yeasts (0.22%) were also 
isolated from urine samples.[9,12,17,25,28,31,33,47,49,53,55,74-77] Furthermore, 
rarely Trichosporum and Saccharomyces were isolated from 
patients’ urine cultures.[73] In addition, recently Moslem et al.[77], 
isolated Rhodotorula species from a patient with candiduria in 
Ahvaz. Furthermore, co-cultures of different species of bacteria 
(Staphylococcus and Escherichia species) with Candida species 
were identified in several investigations.[25,78] 
Although in some reports, candiduria was more commonly seen 
among Iranian female population[9,17,53,75], but overall, our review 
have indicated that candiduria was more prevalent among male 
population with a male:female ratio of 1.2:1. Furthermore, age 
range of the candiduric patients varied between 5 days and 81 
years, however mostly middle aged patients were affected.
[9,12,17,25,28,31,33,47,49,53,55,74-77] 
In conclusion, candiduria due to nosocomial UTI is relatively 
more common among patients with specific predisposing fac-
tors. Host factors (genitourinary abnormality, diabetes mellitus, 
and immunodeficiency) as well as invasive therapy (indwelling 
urinary catheters, widespread systemic antibiotic use, surgery, 
and chemotherapy) have important roles in the prevalence and 
increasing rate of candiduria in patients. Moreover, pathoge-
nicity factors of organisms and specific species, non-albicans 
Candida species (resistance to antifungals), are other factors 
that change the incidence of disease, antifungal susceptibil-
ity and mortality rates. We found that the mean prevalence 
of candiduria among Iranian patients was lower (16.5%) than 
449Gharaghani et al. Candiduria; a review article with specific data from Iran 
worldwide prevalence rate and also males were more frequently 
affected than females (M:F, 1.2:1). Similar to other countries, C. 
albicans was the most common agent followed by non-albicans 
species including, C. glabrata, C. tropicalis and C. krusei. 
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